J
John T. O'Brien
Researcher at University of Cambridge
Publications - 873
Citations - 73158
John T. O'Brien is an academic researcher from University of Cambridge. The author has contributed to research in topics: Dementia & Dementia with Lewy bodies. The author has an hindex of 121, co-authored 819 publications receiving 63242 citations. Previous affiliations of John T. O'Brien include Royal Melbourne Hospital & University of Western Australia.
Papers
More filters
Journal ArticleDOI
A study of wrist-worn activity measurement as a potential real-world biomarker for late-life depression
John T. O'Brien,Peter Gallagher,Daniel Stow,Nils Y. Hammerla,Thomas Ploetz,Michael J. Firbank,Cassim Ladha,Karim Ladha,Dan Jackson,Roisin McNaney,I. N. Ferrier,Patrick Olivier +11 more
TL;DR: This study suggests that novel wearable technology has the potential to provide an objective way of monitoring real-world function and explores the utility of a bespoke activity monitor to characterize activity profiles in LLD more precisely.
Journal ArticleDOI
A Prospective Study of Psychotic Symptoms in Dementia Sufferers: Psychosis in Dementia
TL;DR: A clinical cohort of 124 patients with Diagnostic and Statistical Manual of Mental Disorders (3rd ed., rev.) dementia were followed up at monthly intervals for 1 year, and patients either experienced brief or persistent psychotic disorders.
Journal ArticleDOI
Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications
Christoph Mueller,Christoph Mueller,Gayan Perera,Anto P. Rajkumar,Anto P. Rajkumar,Manorama Bhattarai,Annabel Price,John T. O'Brien,Clive Ballard,Clive Ballard,Robert Stewart,Robert Stewart,Dag Aarsland,Dag Aarsland +13 more
TL;DR: The aim was to describe the risk and duration of hospital admissions in patients with DLB, and compare these to those in Alzheimer's disease (AD) and the general population.
Journal ArticleDOI
Structural neuroimaging studies in late-life depression: a review.
TL;DR: There are neuroimaging changes commonly observed in LLD patients when compared to normal controls, including ventricular enlargement and sulcal widening, and reduction in volume size of frontal lobes, hippocampus and caudate nucleus.
Journal ArticleDOI
Drugs for Alzheimer's disease.
John T. O'Brien,Clive Ballard +1 more
TL;DR: Three cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) have been licensed in the United Kingdom for use in mild to moderate Alzheimer's disease as mentioned in this paper.